PortfoliosLab logoPortfoliosLab logo
ATAI vs. ATYR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ATAI vs. ATYR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atai Life Sciences N.V. (ATAI) and aTyr Pharma, Inc. (ATYR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ATAI achieves a 17.60% return, which is significantly higher than ATYR's -33.60% return.


ATAI

1D
-0.21%
1M
16.18%
YTD
17.60%
6M
24.29%
1Y
93.17%
3Y*
39.81%
5Y*
10Y*

ATYR

1D
-4.87%
1M
-37.61%
YTD
-33.60%
6M
-26.28%
1Y
-89.05%
3Y*
-39.26%
5Y*
-35.20%
10Y*
-36.47%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ATAI vs. ATYR - Yearly Performance Comparison


2026 (YTD)20252024202320222021
ATAI
Atai Life Sciences N.V.
17.60%207.52%-5.67%-46.99%-65.14%-60.77%
ATYR
aTyr Pharma, Inc.
-33.60%-78.37%156.74%-35.62%-70.68%66.00%

Correlation

The correlation between ATAI and ATYR is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.23

Correlation (3Y)
Calculated over the trailing 3-year period

0.27

Correlation (All Time)
Calculated using the full available price history since Jun 21, 2021

0.26

Fundamentals

Market Cap

ATAI:

$1.72B

ATYR:

$50.98M

EPS

ATAI:

-$2.67

ATYR:

-$0.73

PS Ratio

ATAI:

342.57

ATYR:

262.28

PB Ratio

ATAI:

8.65

ATYR:

0.88

Total Revenue (TTM)

ATAI:

$3.49M

ATYR:

$190.00K

Gross Profit (TTM)

ATAI:

$3.49M

ATYR:

-$22.33M

EBITDA (TTM)

ATAI:

-$663.38M

ATYR:

-$71.35M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ATAI vs. ATYR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATAI
ATAI Risk / Return Rank: 7474
Overall Rank
ATAI Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
ATAI Sortino Ratio Rank: 7676
Sortino Ratio Rank
ATAI Omega Ratio Rank: 7373
Omega Ratio Rank
ATAI Calmar Ratio Rank: 7676
Calmar Ratio Rank
ATAI Martin Ratio Rank: 7070
Martin Ratio Rank

ATYR
ATYR Risk / Return Rank: 1313
Overall Rank
ATYR Sharpe Ratio Rank: 1313
Sharpe Ratio Rank
ATYR Sortino Ratio Rank: 1818
Sortino Ratio Rank
ATYR Omega Ratio Rank: 1515
Omega Ratio Rank
ATYR Calmar Ratio Rank: 44
Calmar Ratio Rank
ATYR Martin Ratio Rank: 1414
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATAI vs. ATYR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and aTyr Pharma, Inc. (ATYR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ATAIATYRDifference

Sharpe ratio

Return per unit of total volatility

1.17

-0.64

+1.80

Sortino ratio

Return per unit of downside risk

2.07

-0.55

+2.63

Omega ratio

Gain probability vs. loss probability

1.25

0.90

+0.35

Calmar ratio

Return relative to maximum drawdown

2.25

-0.94

+3.19

Martin ratio

Return relative to average drawdown

3.68

-1.19

+4.87

ATAI vs. ATYR - Sharpe Ratio Comparison

The current ATAI Sharpe Ratio is 1.17, which is higher than the ATYR Sharpe Ratio of -0.64. The chart below compares the historical Sharpe Ratios of ATAI and ATYR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ATAIATYRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.17

-0.64

+1.80

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.39

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.41

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.29

-0.47

+0.18

Drawdowns

ATAI vs. ATYR - Drawdown Comparison

The maximum ATAI drawdown since its inception was -94.77%, smaller than the maximum ATYR drawdown of -99.90%. Use the drawdown chart below to compare losses from any high point for ATAI and ATYR.


Loading charts...

Drawdown Indicators


ATAIATYRDifference

Max Drawdown

Largest peak-to-trough decline

-94.77%

-99.90%

+5.13%

Max Drawdown (1Y)

Largest decline over 1 year

-48.06%

-94.01%

+45.95%

Max Drawdown (3Y)

Largest decline over 3 years

-59.23%

-94.01%

+34.78%

Max Drawdown (5Y)

Largest decline over 5 years

-96.83%

Max Drawdown (10Y)

Largest decline over 10 years

-99.55%

Current Drawdown

Current decline from peak

-75.82%

-99.87%

+24.05%

Average Drawdown

Average peak-to-trough decline

-79.77%

-93.17%

+13.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.40%

74.57%

-45.17%

Volatility

ATAI vs. ATYR - Volatility Comparison

The current volatility for Atai Life Sciences N.V. (ATAI) is 14.87%, while aTyr Pharma, Inc. (ATYR) has a volatility of 82.08%. This indicates that ATAI experiences smaller price fluctuations and is considered to be less risky than ATYR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ATAIATYRDifference

Volatility (1M)

Calculated over the trailing 1-month period

14.87%

82.08%

-67.21%

Volatility (6M)

Calculated over the trailing 6-month period

48.76%

95.21%

-46.45%

Volatility (1Y)

Calculated over the trailing 1-year period

80.75%

140.14%

-59.39%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

83.68%

89.64%

-5.96%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.68%

88.35%

-4.67%

Dividends

ATAI vs. ATYR - Dividend Comparison

Neither ATAI nor ATYR has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ATAI vs. ATYR - Financials Comparison

This section allows you to compare key financial metrics between Atai Life Sciences N.V. and aTyr Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M20222023202420252026
954.00K
0
(ATAI) Total Revenue
(ATYR) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ATAI and ATYR have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ATYR has higher volatility (82.08%) compared to ATAI (14.87%). In terms of maximum drawdown, ATAI dropped -94.77% vs ATYR's -99.90%.

ATAI currently has the higher Sharpe Ratio (1.17 vs -0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ATAI and ATYR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer